Abstract:BACKGROUND: The main aim of this research was to explore the role and mechanism of Andrographolide (Andro) in controlling non-small cell lung cancer (NSCLC) cell proliferation.METHODS: Human NSCLC H1975 cells were treated with Andro (0-20 µM) for 4-72 h. B-cell leukemia/lymphoma 2 (Bcl-2)-antagonist/killer (Bak)-small interfering RNA (siRNA) (Bak-siRNA) and fructose-1,6-bisphosphatase (FBP1)-siRNA were transfected into H1975 cells to inhibit the endogenic Bak and FBP1 expression, respectively, and their expressions were detected by real-time quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and western blotting (WB). Cellular proliferation ability was determined through various assessments, including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), colony formation, and cell counting kit-8 (CCK-8) assays. Cell apoptosis ability was measured using flow cytometry. Pro-apoptotic-related proteins (cleaved caspase 9, cleaved caspase 8, and cleaved caspase 3) and mitochondrial apoptosis pathway proteins [Bcl2-associated X (Bax), Bak, Bcl-2, and cytochrome C (cyto C)] were assessed by WB. Aerobic glycolysis-associated genes [pyruvate kinase M2 (PKM2), lactate dehydrogenase A (LDHA), and glucose transporter 1 (GLUT1)] and gluconeogenesis genes [phosphoenolpyruvate carboxykinase 1 (PEPCK1), fructose-1,6-bisphosphatase 1 (FBP1), and phosphofructokinase (PFK)] were measured by qRT-PCR. The mitochondrial membrane depolarization sensor, 5, 50, 6, 60-tetrachloro-1, 10, 3, 30 tetraethyl benzimidazolo carbocyanine iodide (JC-1) assay was used for the measurement of mitochondrial membrane potential (ΔΨm). Additionally, glycolytic metabolism, lactate production, and adenosine triphosphate (ATP) synthesis were also analyzed.RESULTS: Andro inhibited human NSCLC cellular proliferation and induced apoptosis in a dose-time or dose-dependent manner via activation of the mitochondrial apoptosis pathway. Andro inhibited glycolysis, promoted the gluconeogenesis pathway, and increased the levels of cleaved caspase 9, cleaved caspase 8, cleaved caspase 3, Bax, Bak, PEPCK1, FBP1, and PFK, and decreased the levels of Bcl-2, PKM2, LDHA, and GLUT1. Moreover, it also decreased the ΔΨm and facilitated the release of cyto C from mitochondria into the cytoplasm. Furthermore, Andro enhanced the mitochondrial translocation of Bak, glucose uptake, lactate release, and intracellular ATP synthesis. Suppression of endogenic Bak and FBP1 expression significantly reduced the effects of Andro in H1975 cells.CONCLUSIONS: Andro represses NSCLC cell proliferation through the activation of the mitochondrial apoptosis pathway and by reprogramming glucose metabolism.

Andrographolide sensitizes cisplatin-induced apoptosis via suppression of autophagosome-lysosome fusion in human cancer cells.

Andrographolide Enhances Cisplatin-Mediated Anticancer Effects in Lung Cancer Cells Through Blockade of Autophagy.

Inhibition of Autophagy by Andrographolide Resensitizes Cisplatin-Resistant Non-Small Cell Lung Carcinoma Cells Via Activation of the Akt/mTOR Pathway.

Andrographolide Enhances 5-Fluorouracil-induced Apoptosis Via Caspase-8-dependent Mitochondrial Pathway Involving P53 Participation in Hepatocellular Carcinoma (SMMC-7721) Cells.

Andrographolide Induces Autophagic Cell Death in Human Liver Cancer Cells Through Cyclophilin D-mediated Mitochondrial Permeability Transition Pore.

Andrographolide induces protective autophagy and targeting DJ-1 triggers reactive oxygen species-induced cell death in pancreatic cancer

Andrographis modulates cisplatin resistance in lung cancer via miR-155-5p/SIRT1 axis

Andrographolide Causes p53-independent HCC Cell Death through p62 Accumulation and Impaired DNA Damage Repair

Andrographolide Enhances TRAIL-Induced Apoptosis Via P53-Mediated Death Receptors Up-Regulation and Suppression of the NF-кB Pathway in Bladder Cancer Cells.

Andrographolide Inhibits Breast Cancer Through Suppressing COX-2 Expression and Angiogenesis Via Inactivation of P300 Signaling and VEGF Pathway.

Andrographolide reverts multidrug resistance in KBChR 8‐5 cells through AKT signaling pathway

Andrographolide suppresses non-small-cell lung cancer progression through induction of autophagy and antitumor immune response

Synergistic Effects of Tanshinone IIA and Andrographolide on the Apoptosis of Cancer Cells Via Crosstalk Between P53 and Reactive Oxygen Species Pathways.

Andrographolide enhanced radiosensitivity by downregulating glycolysis via the inhibition of the PI3K-Akt-mTOR signaling pathway in HCT116 colorectal cancer cells

Anti-tumor Effect of Cisplatin in Human Oral Squamous Cell Carcinoma Was Enhanced by Andrographolide Via Upregulation of Phospho-P53 in Vitro and in Vivo

Andrographolide sensitizes prostate cancer cells to TRAIL-induced apoptosis.

Protective effect of Andrographolide on 5-Fu induced intestinal mucositis by regulating p38 MAPK signaling pathway

Andrographolide sensitizes human renal carcinoma cells to TRAIL-induced apoptosis through upregulation of death receptor 4

Oridonin Sensitizes Cisplatin-Induced Apoptosis Via AMPK/Akt/mTOR-Dependent Autophagosome Accumulation in A549 Cells

Andrographolide Inhibits Proliferation and Promotes Apoptosis in Bladder Cancer Cells by Interfering with NF- Κ B and PI3K/AKT Signaling in Vitro and in Vivo.

Andrographolide inhibits non-small cell lung cancer cell proliferation through the activation of the mitochondrial apoptosis pathway and by reprogramming host glucose metabolism